

Prostate Cancer Results Study Group

The prostate cancer study group (PCRSg) comprises experts from key treating disciplines (surgery, external radiation, brachytherapy, high-frequency ultrasound and proton therapy)

- Ignace Billiet, MD**
F.E.B.U.-Urologist, AZ Groeninge Teaching Hospital, Kortrijk, Belgium.

David Bostwick, MD
Bostwick Laboratories, Orlando, FL, USA.

Luis Campos-Pinheiro, MD
Univ. of Lisbon, Lisbon, Portugal.

David Crawford, MD
Univ. Colorado, Denver, CO, USA.

Brian Davis, MD
Mayo Clinic, Rochester, MN, USA.

D. Jeffrey Demanes, MD
UCLA Medical Center, Santa Monica, CA, USA.

Adam Dicker, MD
Thomas Jefferson U., Philadelphia, PA, USA.

Steven Frank, MD
MD Andersen, Houston, TX, USA.

Peter Grimm, DO
Prostate Cancer Center of Seattle, Seattle, WA, USA.
- Gustavo Guimaraes, MD**
AC Camargo Cancer Center, São Paulo, Brazil.

Jos Immerzeel, MD
De Prostaat Kliniek, Netherlands.

Mira Keyes, MD
BC Cancer Agency, Vancouver BC, Canada.

Patrick Kupelian, MD
UCLA Med Center, Los Angeles, CA, USA.

Stephen Langley, MD
St Luke's Cancer Centre, Guildford, England.

Robert Lee, MD
Duke University Medical Center, Durham, NC, USA.

Stefan Machtens, MD
Marien-Krankenhaus Hospital, Bergisch-Gladbach, Germany.

Alvaro Martinez, MD
William Beaumont, Royal Oak, MI, USA.

Jyoti Mayadev, MD
UC Davis, Davis, CA, USA.
- Gregory Merrick, MD**
Schiffler Cancer Center, Wheeling, WV, USA.

Jurgen Metz, MD
Institute for Radiation Oncology, Bergisch-Bladbach, Germany.

Jeremy Millar, MD
Alfred Health Medical Center & Monash University, Melbourne, Australia.

Brian Moran, MD
Chicago Prostate Institute, Chicago, IL, USA.

Antonio Cassio Pellizzon, MD
Camargo Cancer Center, São Paulo, Brazil.

Mack Roach, M
UC San Francisco, San Francisco, CA, USA.

Mark Scholz, MD
Prostate Cancer Research Institute, Marina del Ray, CA, USA.

Katsuto Shinohara, MD
UC San Francisco, San Francisco, CA, USA.
- Janusz Skowronek, MD**
Greater Poland Cancer Center, Pozna, Poland.

Richard Stock, MD
Mt. Sinai, New York, NY, USA.

Frank Sullivan, MD
College of Medicine, Nursing and Health Sciences, NUI, Galway, Ireland.

Jehan Titus, MD
Calvary Hospital, St Josephs Collage, Adelaide, Australia.

Robyn Vera, DO
Radiant Oncology, Lacey, WA, USA.

Edward Weber, MD
Prostate Cancer Center of Seattle, Seattle, WA, USA.

Jason Wong, MD
UC Irvine, Irvine, CA, USA.

Michael Zelefsky, MD
Memorial Sloan Kettering, New York, NY, USA.

Anthony Zietman, MD
Harvard Joint Center, Boston, MA, USA.

Background


Given the wide range of modern treatment options for prostate cancer, there is a need for a simple, unbiased means by which to compare the cancer control rates they offer.

The PCRSg has undertaken a comprehensive review of the current literature on prostate cancer treatment in order to provide this comparison.

Study Design

All Treatments Considered:

- RP (standard/robotic)
- EBRT (including IMRT)
- HIFU
- LDR brachytherapy
- HDR brachytherapy
- Cryotherapy
- Proton therapy



Inclusion Criteria:

- Patients separated into:
 - low-risk (≥100 pts)
 - intermediate-risk (≥100 pts)
 - high-risk (≥50 pts)
- Treatment success determined by PSA**
- Patients must have been followed for a median of 5 years
- Peer-reviewed publication

Glossary:

- EBRT:** External beam radiation therapy
- HDR brachytherapy:** High-dose rate brachytherapy
- HIFU:** High-intensity focused ultrasound
- IMRT:** Intensity-modulated radiotherapy
- LDR brachytherapy:** Low-dose rate brachytherapy
- RP:** Radical prostatectomy

* Some treatments under represented in the evaluation due to failure to meet the inclusion criteria

** Different treatments lead to different patterns of PSA reduction, resulting in different methods of using PSA numbers to evaluate treatment success. No attempt was made to standardise these evaluation methods across treatments


Prostate Cancer Results Study Group

Treatment success

- Treatment Success % = percent of men whose PSA numbers indicate no cancer progression (progression free) at a specific point in time.

Ellipses

- Treatment results for a treatment are grouped and mathematically analyzed to see if the data clusters.
- These “ellipses” outline the treatment results allowing you to see the average result and trend of the treatment over time.
- Ellipses can only be done if there are 4 or more reported studies, so some treatments may not appear on the slides as ellipses.



Brachytherapy

- Brachytherapy alone
- Brachytherapy & EBRT
- Brachytherapy, EBRT, & ADT

EBRT/IMRT

- EBRT alone
- EBRT & ADT
- Hypo EBRT

Protons



- Protons

Surgery

- RP Surgery
- Robotic Surgery

HIFU

- HIFU



For more information or to view by single therapy please visit www.pctrf.org/comparing-treatments

Conclusions

- For most low risk patients, most therapies will be successful.
- There appears to be a higher cancer control success rate for Brachy over EBRT and Surgery for all groups. Patients are encouraged to look at graphs and determine for themselves.
- Serious side effect rates must be considered for any treatment.